{"filing":{"accession_number":"0001628280-26-043416","cik":"0001576885","ticker":"ABOS","company_name":"Acumen Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"abos-20260612.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026043416/abos-20260612.htm"},"events":[{"id":11198,"run_id":9818,"accession_number":"0001628280-26-043416","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Acumen announced the nomination of two enhanced brain delivery (EBD) development candidates for Alzheimer's disease and exercised its option to license and develop them under its JCR collaboration agreement, combining the company's AβO-selective antibody expertise with JCR's J-Brain Cargo blood-brain-barrier technology. Preclinical data demonstrated enhanced brain penetration (14-40x higher antibody levels in non-human primates) and favorable safety profiles, representing a material advancement in the company's pipeline and strategic positioning.","company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7732,"accession_number":"0001628280-26-043416","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Acumen announced the nomination of two enhanced brain delivery development candidates for Alzheimer's disease and exercised its option to license and develop them under a JCR collaboration agreement. This represents a material advancement in the company's pipeline and strategic development activities, but does not fit neatly into the more specific event categories (it is neither a completed M\u0026A transaction, an earnings release, nor an executive change). The disclosure of pipeline advancement and option exercise is material to investors assessing the company's development progress and strategic positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T11:35:08.504661+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7733,"accession_number":"0001628280-26-043416","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company announced nomination and exercise of an option to license and develop two EBD development candidates for Alzheimer's disease treatment under its JCR collaboration agreement. This represents a material advancement in the Company's pipeline combining its AβO-selective antibody expertise with JCR's J-Brain Cargo blood-brain-barrier technology, with preclinical data showing enhanced brain penetration (14-40x higher antibody levels in NHPs) and favorable safety profiles. While this is a significant pipeline development event, it does not fit neatly into the more specific categories (not an M\u0026A transaction, not an earnings release, not an executive change, not a restatement or impairment), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T11:35:08.504661+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7732,"accession_number":"0001628280-26-043416","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Acumen announced the nomination of two enhanced brain delivery development candidates for Alzheimer's disease and exercised its option to license and develop them under a JCR collaboration agreement. This represents a material advancement in the company's pipeline and strategic development activities, but does not fit neatly into the more specific event categories (it is neither a completed M\u0026A transaction, an earnings release, nor an executive change). The disclosure of pipeline advancement and option exercise is material to investors assessing the company's development progress and strategic positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T11:35:08.504661+00:00","company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","filing_date":"2026-06-16"},{"id":7733,"accession_number":"0001628280-26-043416","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company announced nomination and exercise of an option to license and develop two EBD development candidates for Alzheimer's disease treatment under its JCR collaboration agreement. This represents a material advancement in the Company's pipeline combining its AβO-selective antibody expertise with JCR's J-Brain Cargo blood-brain-barrier technology, with preclinical data showing enhanced brain penetration (14-40x higher antibody levels in NHPs) and favorable safety profiles. While this is a significant pipeline development event, it does not fit neatly into the more specific categories (not an M\u0026A transaction, not an earnings release, not an executive change, not a restatement or impairment), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T11:35:08.504661+00:00","company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","filing_date":"2026-06-16"}]}